4 ottobre 2012, Budapest e Debrecen
CEO Erik Bogsch reviewed Gedeon Richter Plc.’s financial performance and R&D portfolio at an international press conference held by Richter today. The Hungary-based multinational pharmaceutical company then presented journalists its new Biotechnology Plant, built in the Hungarian city of Debrecen with a near 90 million euro investment and inaugurated this spring. The state-of-the-art facility will initially produce samples for clinical tests with the use of mammalian cells and will begin to manufacture drugs for treating human diseases.
Erik Bogsch stressed that last year, for the first time in the company’s history, Richter’s turnover exceeded 1 billion euros. The CEO called the market launch of the new product Esmya in various European countries as well as the expansion of the Western European sales & marketing network a great success. It was also highlighted that the company’s capital spending amounted to 750 million euros in the past few years. Erik Bogsch pointed out that shrinking opportunities in traditional innovation and increasing generic competition in the pharmaceutical industry highlight the crucial importance of new fi elds, such as biotechnology, which offer business opportunities for companies that think long term. Richter has been making use of biotechnological processes for more than forty years. The company has great traditions and a large pool of experts in both development and manufacturing, and it is the most important corporate innovation base in the region. On average, Richter spends 10% of its sales revenue on R&D. “Richter’s strategic goal is to create a complex and competitive biotechnological product line which will help to expand its portfolio with high added value products. The Debrecen plant has made biotechnological manufacturing more competitive, which helps to implement Hungary’s biotechnology strategy and contributes to increasing Hungary’s competitiveness,” CEO Erik Bogsch said, underlining the importance of the plant.
The plant complies with the most recent international quality, safety and environmental standards for pharmaceutical manufacturing. The facility has created 120 new jobs for highly qualified professionals. The Biotechnology Plant was built with government aid in an easily accessible industrial zone furnished with all necessary infrastructure. The plant, whose impact on the environment is minimal, will initially produce samples for clinical trials. The manufacture of commercial products with high intellectual and technological added value is slated to begin in 2014. These drugs will be protein products made from mammalian cells grown in bioreactors, such as antibodies for treating cancer and chronic inflammatory diseases.
The significance of biotechnology products continues unabated in the global pharmaceutical market. Twenty-eight per cent of the products given marketing authorisation between November 2010 and October 2011 in the US and one-third of all the new drugs in the EU are of biotechnological origin. Experts unanimously agree that the market share of biotechnology products will continue to grow in the future. While the small-molecule drug market is estimated to grow by 3.9% annually between now and 2015, the market for biotechnology products is expected to grow by more than 10% a year. The trend is further bolstered by the fact that approximately one-third of the current clinical development topics are of biotechnological origin. According to competent estimates, seven of the world’s top ten drugs will be of biotechnological origin by 2016. These forecasts and data unequivocally support Richter’s strategic decision to create a biotechnology portfolio and establish a Biotechnology Plant.